Galecto, Inc. is a clinical stage biotechnology company focusing on the development of novel small molecule therapeutics for fibrosis, inflammation, and cancer. Founded in 2011 by leading fibrosis-focused scientists and biotech executives, Galecto has over 10 years of research experience in galectin and fibrosis modulators. The company's deep understanding of the galectin family of proteins and the LOXL2 enzyme enables them to target complex, devastating diseases at their biological core.
Galecto has garnered significant support from a range of prominent investors, including Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure, and SEED Capital. The most recent funding round, a $64.00M Series D investment on 25 September 2020, saw participation from HBM Healthcare Investments, Seventure Partners, OrbiMed, Canica, Eir Ventures, Hadean Partners, Janus Handerson, Ysios Capital, Bristol-Myers Squibb, and Sphera Funds Management.
Galecto's commitment to advancing treatment options for fibrosis and cancer, along with its strong financial backing and experienced team, positions the company as a promising player in the biotechnology and healthcare industries.
